Oral montelukast sodium versus inhaled fluticasone propionate in adults with mild persistent asthma

Journal of Applied Research

Volumn 5, Issue 3, 2005, Pages 402-414

  Bousquet, Jean ^a   Menten, Joris ^b   Tozzi, Carol A ^b   Polos, Peter G ^b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

agonist; Asthma; FEV1; Fluticasone; Montelukast

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE; MONTELUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MILD PERSISTENT ASTHMA; MULTICENTER STUDY; MULTIVARIATE ANALYSIS OF COVARIANCE; OPEN STUDY; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYMPTOM; TREATMENT OUTCOME; WAKEFULNESS;

EID: 26844432297     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. N.I.H. Publication No. 97-4051. Bethesda, MD: National Institutes of Health, 1997.
2. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. NIH Publication No. 96-3659B. Bethesda MD: National Institutes of Health, 1998.
3. Vignola AM, Chanez P, Campbell AM, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998;157:403-409.
4. Warke TJ, Fitch PS, Brown V, et al. Outgrown asthma does not mean no airways inflammation. Eur Respir J 2002;19:284-287.
5. van den Toorn LM, Prins JB, Overbeek SE, et al. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000;162:953-957.
6. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
7. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
8. Reiss TF, Chervinsky P, Dockhorn RJ, et al, for the Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-1220.
9. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 1998;279:1181-1186.
10. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:1-10.
11. Nayak AS, Philip G, Lu S, et al, and the Montelukast Fall Rhinitis Investigator Group. Ann Allergy Asthma Immunol 2002;88:592-600.
12. Philip G, Malmstrom K, Hampel FC Jr, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-1028.
13. van Adelsberg J, Philip G, LaForce CF, et al and the Montelukast Spring Rhinitis Investigator Group. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-222.
14. van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-1276.
15. Zhang J, Yu C, Noonan G, Reiss TF. Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability. Clin Ther 2002;24:574-582.
16. Shingo S, Zhang J, Reiss TF. Correlation of airway obstruction and patient-reported endpoints in clinical studies. Eur Respir J 2001;17:220-224.
17. Zeiger RS, Bird SR, Kaplan MS, et al, for the Mild Asthma Montelukast Versus Inhaled Corticosteroid (MIAMI) Research Group. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: results from the mild asthma montelukast versus inhaled corticosteroid (MIAMI) study. Am J Med. 2005;118:649-657.
18. Lipworth BJ. Systemic adverse effects of inhaled Corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-955.
19. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-208.
20. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone mineral density in premenopausal women. N Engl J Med 2001;345:941-947.
21. Jonasson G, Carlsen K-H, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000;83:330-333.
22. Santanello NC, Barber BL, Reiss TF, et al. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997;10:646-651.
23. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47(2):76-83.
24. Moy ML, Israel E, Weiss ST, et al, and the NHLBI Asthma Clinical Research Network. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med 2001;163:924-929.
25. Barnes N, Wei LX, Reiss TF, et al. Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med 2001;95:379-386.
26. Bousquet J, Chanez P, Vignola AM, et al. Eosinophil inflammation in asthma. Am Rev Respir Crit Care Med 1994;150:933-938.
27. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am Rev Respir Crit Care Med 1999;160:1862-1868.
28. Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma: reduction the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am Rev Respir Crit Care Med 1996;153, 551-556.
29. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am J Respir Crit Care Med 1992;145:669-674.